In a second mesenchymal NSCLC cell line (H1792), the HGF neutralizing antibody did reduce basal cMet activation consistent with cancer cell production of HGF leading to cMet activation that has previously been well established in some NSCLC tumors (Salgia, 2017). This evidence concerns the gene MET and cancer.